Neuroblastoma is an embryonal tumor of the sympathetic nervous system and the most common extracranial tumor of childhood. By sequencing transcriptomes of low-and high-risk neuroblastomas, we detected differentially expressed annotated and nonannotated long noncoding RNAs (lncRNAs). We identified a lncRNA neuroblastoma associated transcript-1 (NBAT-1) as a biomarker significantly predicting clinical outcome of neuroblastoma. CpG methylation and a high-risk neuroblastoma associated SNP on chromosome 6p22 functionally contribute to NBAT-1 differential expression. Loss of NBAT-1 increases cellular proliferation and invasion. It controls these processes via epigenetic silencing of target genes. NBAT-1 loss affects neuronal differentiation through activation of the neuronal-specific transcription factor NRSF/REST. Thus, loss of NBAT-1 contributes to aggressive neuroblastoma by increasing proliferation and impairing differentiation of neuronal precursors.
INTRODUCTION
Neuroblastoma is one of the most common extracranial solid tumors in children. It is thought to arise from improper differentia-tion of neuronal precursor cells of the sympathetic nervous system. These tumors most commonly occur in the adrenal medulla, but also in sympathetic ganglia of the abdominal organs and of the sympathetic trunk (Brodeur, 2003; Kamijo and Nakagawara, 2012) . Features like age of the patient at diagnosis, stage of the disease, and nonrandom chromosomal aberrations are well-established parameters for stratification of risk and treatment as well as for predicting the disease outcome in patients (Cohn et al., 2009; Monclair et al., 2009) . Neuroblastoma patients with nonrandom chromosomal alterations MNA (MYCN amplification)/1p (shorter arm of the chromosome 1) deletion/17q (longer arm of the chromosome 17) gain (seen in 20% of patients) or 11q deletion (11q-) /17q gain (seen in 30% of patients) are often associated with high-risk tumors and an unfavorable outcome. Tumors with hyperdiploidy and numerical aberrations of whole chromosomes are associated with low-risk clinical stages and are prognostically favorable (Brodeur et al., 1984; Caré n et al., 2010; Caron, 1995; Guo et al., 1999; Lastowska et al., 2001; Spitz et al., 2003) . In addition to nonrandom chromosomal alterations, some neuroblastomas (7%) display recurrent point mutations in the tyrosine kinase domain of the anaplastic lymphoma kinase gene (Caré n et al., 2008a; Chen et al., 2008; George et al., 2008; Janoueix-Lerosey et al., 2008; Mossé et al., 2008; Wang et al., 2012a) , and genes that take part in neuritogenesis (Molenaar et al., 2012) . Recent genome-wide association studies on large patient cohorts have also uncovered clusters of germline SNPs, in six genomic regions. Three SNPs from these clusters map to 6p22 region, and one of the SNPs rs6939340 is located in intronic region of a lncRNA LOC729177. Neuroblastoma patients with homozygous risk G allele at the SNP: rs6939340 are likely to have metastatic disease and poor event free survival (Diskin et al., 2012; Maris et al., 2008) . Besides nonrandom somatic genomic alterations and germline SNPs, array based gene expression profiles have also shown associations with clinical subtypes (Fischer et al., 2008) .
In the light of current transcriptomic studies, it is evident that the major part of the transcribed genome is noncoding. The RNA from the nonprotein coding genome is mainly comprised of small ncRNAs, long noncoding RNAs (lncRNAs), and unannotated intergenic transcribed regions. LncRNAs have been implicated in diverse cellular processes with distinct regulatory roles (Kanduri, 2011; Whitehead et al., 2009) . Several lncRNAs, for example PCAT-1, MALAT1, HOTAIR, and ANRIL, have been implicated in tumorigenesis (Batista and Chang, 2013; Prensner and Chinnaiyan, 2011; Spizzo et al., 2012; Taft et al., 2010) . Thus, studying and evaluating the expression of these nontranslated regions could be of profound value in terms of disease characterization. We therefore set out to identify lncRNA-based biomarkers that could be used in neuroblastoma risk assessment and therapy.
RESULTS

Identification of Transcripts Specific to Distinct Subtypes of Neuroblastomas
In this study, we performed high-throughput transcriptomic profiling of 15 neuroblastoma tumors, three of which were lowrisk, whereas of the remaining 12, six each were of the MNA or 11q high-risk subtypes (Caré n et al., 2010) . An unsupervised clustering analysis on all transcripts detected significant differences in expression signatures between low-and high-risk tumors, as well as between the two subtypes of high-risk tumors ( Figures 1A and 1B and Figure S1 available online), indicating that each neuroblastoma subtype carries unique gene expression signatures. We analyzed relative expression of protein coding, annotated and nonannotated lncRNAs by considering the following comparisons of neuroblastoma tumors: low-risk versus 11q-, low-risk versus MNA, low-risk versus high-risk subtypes, and 11q-versus MNA. These comparisons revealed several differentially expressed transcripts (false discovery rate [FDR] < 0.1) ( Figures 1C and 1D ). We found a significant overlap for protein coding genes between our analysis and the published microarray data set based on expression profile of 88 primary neuroblastoma tumors (R2 database http://r2.amc.nl) (Table S1 ). We performed pathway analysis on differentially expressed protein coding genes and found eight low-risk specific, 25 11q-specific, and five MNA specific pathways with significant p values from the comparisons between the three subtypes as shown in Figures 1A and S1; Table S2 . Mutational screening of genes differentially expressed in this study showed that 27.4% (194/707) carried somatically acquired SNP or insertion and deletion variations predicted to result in nonsilent changes of coding regions, either in our exome sequencing study or previously published neuroblastoma (NBL) sets of 13 and 349 tumors, respectively, (Molenaar et al., 2012; Pugh et al., 2013; Sausen et al., 2013) in comparison to 19.3% (3,787/19,638) of nondifferentially expressed genes. Of the 707 differentially expressed genes, 11 genes (1.56%) (ALK, MUC4, AHNAK2, AHNAK, DOCK8, FBN2, HSPG2, MYCN, TNC, KIAA0319, and ODZ4) showed a mutation frequency >1% with most recurrent mutations in ALK, concordant with previous studies, whereas 61 genes (0.31%) of the nondifferentially expressed showed mutation frequency >1% with most recurrent mutations in MUC16 (6.6%) and TTN (5.8%) (Table S3 ). However, when we applied the MutSigCV v1.3 algorithm (Lawrence et al., 2013) for all NBL sets, only the differentially expressed ALK and the nondifferentially expressed ZNF717 were found to be significantly mutated. Since the MutSigCV algorithm was developed against tumors with high frequency of mutations, functional significance of rare mutations identified in this study remains to be investigated in pediatric tumors, which are known to harbor few somatic mutations.
The Expression Profile of Nonannotated Long Noncoding RNAs Distinguishes between Low-Risk and High-Risk Neuroblastoma
Differential expression analysis of lncRNAs between low-and high-risk neuroblastomas revealed 24 nonannotated lncRNAs (named as CUFF 1-24) ( Figure S2A ). As can be seen in the heatmap (Figure 2A ), the expression profiles of these nonannotated lncRNAs clearly distinguish these two subtypes of tumors. The relative expression of four of these transcripts is depicted in box plots ( Figure S2B ). We validated their differential expression in an independent cohort of 23 primary neuroblastoma tumors representing low-and high-risk subtypes ( Figure 2B ). Interestingly, many of these transcripts (9 of the 24) map to the chromosome 6q arm and show significant overexpression in high-risk neuroblastomas compared to the low-risk subset ( Figure S2C ). The Array comparative genomic hybridization (CGH) profiles of the sequenced tumors did not show any genomic alterations at these transcribed regions.
As lncRNAs are known to be expressed at lower levels in comparison to protein coding transcripts, many lncRNAs tend to filter out in differential expression analysis. Therefore to increase the sensitivity for detecting differentially expressed lncRNAs, we repeated the analyses exclusively on the lncRNA subset. These analyses revealed 325 and 130 differentially expressed lncRNAs between low-risk versus MNA tumors, and low-risk versus 11qtumors, respectively (Figures S2D and S2E; Table S4 ). We next investigated whether any of the differentially expressed lncRNAs from low-versus high-risk comparisons map to the characteristic chromosomal abnormalities. We identified a 2 kilobases (kb) lncRNA; mapping to the coamplified region located 293 kb from the MYCN locus (Caré n et al., 2008b; Schwab, 1998) . Similar to MYCN, this lncRNA is overexpressed in MNA tumors as compared to the sequenced low-risk and 11q-tumors (Figures 2C, 2D, S2F, and S2G) . We observed a similar overexpression of the lncRNA in an independent set of five MNA tumors compared to the low-risk and 11q-tumors ( Figure S2G ). The hemizygous deletion of the 11q23 arm is another well-known genomic aberration observed in case of non-MNA aggressive tumors (Guo et al., 1999) . We detected a lncRNA with significant differential expression mapping to the deleted 11q23 region, showing lower expression in the 11q-tumors compared to the low-risk tumors (Figures 2E, S2H , and S2I). Deletions in the 1p arm are also known to be associated with aggressive neuroblastomas. We identified five additional lncRNAs at the proximal end of the 1p arm with low expression in MNA tumors compared to 11q-and low-risk tumors ( Figure 2F ). So we are able to provide a putative list of differentially expressed nonannotated and annotated lncRNAs that map to genomic regions that are prone to alterations in high-risk aggressive neuroblastoma tumors.
Neuroblastoma Associated Transcript-1 Is a Potential Marker for Risk Assessment in Neuroblastoma
Our analyses on MNA and low-risk tumors revealed LOC729177 (GENCODE annotation, also referred to as CASC14) lncRNA as one of the top ranked candidates with a significant p value (Table  S5 ; p = 0.0012). This transcript also appears as a differentially expressed candidate between low-and high-risk tumors (p = 0.002); it is expressed at low level in high-risk tumors compared to low-risk tumors. Because the lncRNA harbors the high-risk associated SNP: rs6939340 in its intron, we were interested in Figure S1 and Tables S1, S2, and S3. 
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Long Noncoding RNAs in Neuroblastoma Pathogenesis understanding the functional connection between the SNP and LOC729177 and the role of LOC729177 in neuroblastoma pathogenesis. Due to its association with neuroblastoma prognosis, we named this RNA as neuroblastoma associated transcript 1 (NBAT-1). Using the codon substitution matrix and Coding Potential Assessment Tool (CPAT), as well as a comparison with known protein sequences (Swiss-prot), we have evidence that NBAT-1 is a noncoding transcript ( Figures S3A and S3B) (Wang et al., 2013) . The PhastCons score (Pollard et al., 2010) demonstrates that some regions of NBAT-1 are similar across mammalian species, indicating a possible evolutionarily conserved function (Figure S3C) . It has tissue specific expression, mainly in the brain, breast, and ovary ( Figure S3D ). Consistent with our sequencing data; we observed a significantly lower expression of the NBAT-1 in high-risk tumors compared to the non high-risk tumors when analyzed in a clinical cohort comprising 93 neuroblastoma patients ( Figure 3A ). We further validated NBAT-1 differential expression in RNA sequencing data obtained from an independent clinical cohort of 498 neuroblastomas ( Figures 3B, 3C , S3E, and S3F). Analysis of the prognostic value of NBAT-1 indicated that patients with high NBAT-1 expression were associated with good prognosis (5 year overall survival [OS] of 0.86 ± 0.02, and 5 year event free survival [EFS] 0.74 ± 0.03) as compared to patients with low NBAT-1 expression (5 year OS of 0.66 ± 0.04, and 5 year EFS of 0.44 ± 0.04) ( Figures 3D-3F and S3G ). Furthermore, the waterfall plot for ordered NBAT-1 expression across all analyzed tumors with patient outcome corroborates the findings from the survival analysis ( Figures 3G and S3H) . Importantly, the multivariate Cox regression analysis on the independent clinical cohort (n = 498, hazard ratio = 0.839, and p = 0.038) suggests that NBAT-1 may act as an independent prognostic marker in predicting event free survival ( Figure 3H ). In addition, NBAT-1 could give prognostic information for children with both MNA+ and MNA-tumors ( Figures S3I-S3L ). This indicates that NBAT-1 expression is a significant independent prognostic factor that could serve as an additional prognostic marker for risk assessment in neuroblastoma patients.
We next sought to address the functional link between the high-risk neuroblastoma associated SNP: rs6939340 and NBAT-1 expression in primary tumors. We sequenced genomic DNA over the SNP from 51 high-risk primary tumors used in the quantitative reverse transcription (qRT)-PCR validation. Highrisk tumors with either A/G or A/A genotype had higher expression in comparison to tumors with G/G genotype (p = 0.03) ( Figures 4A and S4A ). Thus, G/G genotype might be associated with lower NBAT-1 expression in high-risk tumors. We next genotyped the SNP and analyzed the NBAT-1 expression in six neuroblastoma cell lines ( Figure 4B ). The SK-N-FI cell line with a G/G genotype showed lower NBAT-1 expression compared to the SH-SY5Y cell line with an A/A genotype. In addition, fragments carrying the SNP generated more luciferase activity in PGL3 promoter vectors, with an A/A genotype showing more luciferase activity than the G/G genotype, indicating that the region spanning the SNP might be a putative enhancer element ( Figure 4C ). In addition, higher order regulatory interactions between the SNP and NBAT-1 promoter were detected in a chromosome conformation capture (3C) experiment and in RNA polymerase II chromatin interaction analysis by paired-end tags (PolII ChIA-PET) using the ENCODE data set in MCF7 cells (Li et al., 2012) (Figure 4D) . The SNP region also carries characteristic enhancerspecific marks ( Figure 4E ). The enrichment of enhancer specific marks and 3C interaction was significantly lower in G/G as compared to the A/A genotype (Figures 4D and 4E) .
We next investigated additional factors that contribute toward differential NBAT-1 expression between low-and high-risk neuroblastoma patients by analyzing DNA methylation at CpG nucleotide sites flanking the NBAT-1 promoter using pyrosequencing. We found that five CpGs flanking the NBAT-1 promoter were significantly hypermethylated in high-risk patients, with lower NBAT-1 expression; whereas the CpGs were hypomethylated in low-risk patients with higher NBAT-1 expression ( Figures 4F and S4B-S4F ). In addition, significant activation of the NBAT-1 expression was detected in SK-N-AS cells upon treatment with DNA demethylating agent 5-Aza-2 0 -deoxycytidine (DAC). These observations together suggest that DNA methylation plays a functional role in the inactivation of the NBAT-1 promoter in high-risk patients ( Figure 4G ).
Neuroblastoma Associated Transcript-1 Harbors Tumor Suppressor Properties
Since the lower expression of NBAT-1 is correlated with aggressiveness in neuroblastoma patient tumors, we investigated the effect of downregulation of NBAT-1 on the SH-SY5Y cells. Depletion of NBAT-1 using two siRNAs (si-A and si-C) in the SH-SY5Y cell line resulted in a significant increase in the number of viable cells compared to the cells transfected with control siRNA ( Figures 5A and S5A ). In addition, we generated a SH-SY5Y cell line stably transduced with lentivirus carrying NBAT-1 specific short hairpin RNA (NBAT1-sh) that displays a 70% to 80% downregulation of NBAT-1 compared to the cell line stably transduced with lentivirus containing a scrambled short hairpin 
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Long Noncoding RNAs in Neuroblastoma Pathogenesis RNA (Cntrl-sh) (data not shown). The NBAT-1 shRNA transduced SH-SY5Y cell line also showed a similar increase in the number of viable cells, further confirming the antiproliferative activity of NBAT-1 ( Figure S5B ). Suppression of NBAT-1 expression also led to increased invasiveness of SH-SY5Y cells ( Figure 5B ). Consistent with its antiproliferative property, we observed a significant increase in the growth rate of NBAT-1 depleted xenografts ( Figures 5C-5E ). Hematoxylin and eosin staining of xenograft sections of the NBAT1-sh and Cntrl-sh xenografts did not reveal any gross morphological abnormalities ( Figure 5F ). However, using Ki67, a marker for cell proliferation, we observed a significant increase in the number of replicating cells in NBAT-1 depleted xenografts as compared to control xenografts ( Figures 5F and 5G ). Together, these findings indicate that NBAT-1 harbors tumor suppressor properties. In order to identify the putative targets of NBAT-1 and to understand its inhibitory role in tumorigenesis, we sequenced the total RNA from NBAT1-sh cells along with Cntrl-sh cells. There were 1,348 (987 upregulated and 361 downregulated) proteincoding genes (2-fold expression difference, FDR of < 0.05) that showed differential expression upon NBAT-1 downregulation ( Figures S5C and S5D ; Table S6 ). Importantly, the neighboring transcript LINC00340 (CASC15) was not significantly affected upon NBAT-1's downregulation (data not shown). Gene ontology analysis of the differentially expressed genes showed significant enrichment for biological processes such as cell differentiation, cell migration, and cell proliferation, along with neuronal processes; nervous system development, neurogenesis, and neuron differentiation (FDR < 0.05) ( Figure 5H ). Given that abnormal cell proliferation and migration are among the important contributing factors underlying tumor initiation and progression, we addressed plausible mechanisms by which NBAT-1 controls these biological processes. We noted that 49 (out of 335 genes; 15%) cell proliferation-specific genes and 57 genes implicated in cell migration (121 genes; 47%) were among the 1,348 differentially expressed NBAT-1 target genes (Figures 5I and 5J; Table S6 ). Differential expression of some of the key target genes was validated upon NBAT-1 downregulation using sh-RNA and two siRNAs (si-A and si-C) ( Figures 5K and S5E ), including VCAN, SOX9, and OSMR, which are reported to be overexpressed in a wide range of tumors (Cheon et al., 2014; Kopp et al., 2012; Matheu et al., 2012; West et al., 2012; Yeung et al., 2013) . Interestingly, when the gene expression changes after NBAT-1 downregulation were compared with the R2 data set (comprising differential expression of protein coding genes between low-and high-risk tumors), 45 common candidate genes were found to have similar expression profiles, including VCAN and SOX9 (with a p < 0.05) ( Figure 5L ).
To address the significance of these cancer-related genes in neuroblastoma, they were downregulated in NBAT1-sh cells using siRNAs ( Figures S5F-S5H ). As can be seen in Figure 5M , downregulation of SOX9 and OSMR, but not VCAN affected the proliferation potential of the NBAT1-sh cells. Interestingly, downregulation of VCAN, SOX9, and OSMR also affected the invasive capacity of NBAT1-sh cells ( Figure 5N ). These results, taken together, suggest that higher expression of SOX9, VCAN, and OSMR may contribute to tumor progression in high-risk neuroblastoma patients.
To further understand the functional role of NBAT-1 in tumor suppression and invasion, we have ectopically expressed NBAT-1 in the neuroblastoma cell lines SK-N-AS and SK-N-BE(2), representing the two high-risk neuroblastoma subsets 11q-and MNA, respectively (Caré n et al., 2010) . NBAT-1 overexpression resulted in decreased cell proliferation and invasion ( Figures S5I-S5P ), further corroborating its functional role in tumor progression. Interestingly, we observed consistent downregulation of SOX9 and VCAN in both cell lines, indicating that NBAT-1 may execute tumor suppression via repressing SOX9 and VCAN genes.
We next sought to understand the mechanisms by which NBAT-1 represses genes involved in tumor progression. To this end, RNA immunoprecipiation assay (RIP) demonstrated an interaction between NBAT-1 and PRC2 complex member EZH2 ( Figure 6A ). To further understand the functional connection between NBAT-1 and EZH2, total RNA from the EZH2 downregulated SHSY-5Y cells was sequenced and investigated to see if there is any functional overlap between the expression changes seen in EZH2 and NBAT-1 downregulated cells (Table  S7 ). These two data sets showed significant overlap (r = 0.67) ( Figures 6B and 6C ). Interestingly, a large majority of the overlapped genes were also enriched with H3K27me3 modification (Egan et al., 2013) (Figure 6C ; Table S7 ). Genes implicated in cell proliferation and cell migration were upregulated in both NBAT-1 and EZH2 downregulated cells (Figures 5K, S5Q , and S5R). H3K27me3 modification at the promoters of some of these genes was analyzed upon NBAT-1 downregulation using chromatin immunoprecipitation (ChIP)-qPCR ( Figures 6D and 6E ). Loss of H3K27me3 modification was observed at the promoter regions in NBAT-sh cells, indicating that the NBAT-1/EZH2 functional interaction suppresses its target genes implicated in cell proliferation and cell migration via chromatin level regulation.
Neuroblastoma Associated Transcript-1 Expression Is Critical for Neuronal Differentiation of Neuroblastoma Cells
As mentioned earlier in Figure 5H , neuronal processes are among the top biological processes that were perturbed upon NBAT-1 knockdown. To investigate the functional role of NBAT-1 in neuronal differentiation, we utilized SH-SY5Y cells' ability to differentiate into neurons upon retinoic acid (RA) treat-ment. Analysis of NBAT-1 expression during the course of neuronal differentiation after the treatment of the SH-SY5Y cells with RA for up to 10 days revealed a significant increase in the 
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Long Noncoding RNAs in Neuroblastoma Pathogenesis expression of NBAT-1 ( Figure 7A ). Downregulation of NBAT-1 in SH-SY5Y cells resulted in the impairment of the neuronal differentiation process, as these cells showed loss of expression of neuronal markers (TH, TAU, MAPK, and NSE) and impaired neurite outgrowth, a characteristic feature of neuronal differentiation ( Figures 7A-7C and S6A-S6C) . In order to gain further insights into the functional role of NBAT-1 in the neuronal differentiation, total RNA from Cntrl-sh and NBAT1-sh cells, treated with RA for 0, 4, and 7 days, was sequenced. Expected expression patterns of known neuronal markers were found in the RA treated Cntrl-sh cells ( Figures S6D-S6G ). We observed 136 differentially expressed protein-coding genes between D0, D4, and D7 RA treated Cntrl-sh cells ( Figure S6D) , whereas in the case of RA treated NBAT1-sh cells, only 78 protein-coding genes were differentially expressed (2-fold; FDR < 0.05) (data not shown). Gene ontology (GO) analysis of the 136 genes from RA treated Cntrl-sh cells revealed enrichment of major neuronal processes such as neuronal differentiation, axonogenesis, neurogenesis, etc. No such significant enrichment of neuronal processes was found with NBAT1-sh cells ( Figure 7D ), again indicating that NBAT-1 plays an important role in neuronal differentiation.
To obtain further insights into NBAT-1 mediated neuronal differentiation, we chose to stably overexpress NBAT-1 in the SK-N-AS and SK-N-BE(2) cell lines. NBAT-1 overexpression induced neuronal differentiation of both cell lines, underscoring the importance of NBAT-1 in neuronal differentiation ( Figures  S6H-S6O ).
In order to identify genes/networks perturbed in the NBAT1-sh cells during RA induced neural differentiation, we have clustered the differentially expressed genes (1,956 genes) between Cntrlsh and NBAT1-sh cells at D0, D4, and D7 ( Figures 7E and 7F) . The clustering resulted in five gene clusters with distinct expression patterns. Interestingly, the cluster IV genes (455 genes) with reduced expression levels at D4 and D7 showed significant enrichment for biological processes such as neuron differentiation, neurogenesis, axonogenesis, and nervous system development ( Figure 7G ; Table S8 ). We validated the expression of some of the key neuronal genes representing cluster IV using qRT-PCR ( Figure 7H ). We next investigated whether the NBAT-1/EZH2 functional interaction has any role in neuronal differentiation. Although a significant overlap was found between the cluster IV genes and the EZH2 deregulated gene data set, there was a significant difference in the pattern of expression among the overlapped genes. In the NBAT-1 gene data set, 63% of the overlapped genes show downregulation, whereas in the EZH2 data set, 71% of the overlapped genes show increased expression ( Figure S6P ). More importantly, none of the cluster IV genes showed overlap with H3K27me3 ChIP followed by DNA sequencing (seq)-peaks. These observations indicate that NBAT-1 and EZH2 play critical roles in neurogenesis, but their functional interaction has no role in the regulation of neurogenesis.
We next sought to address the reasons underlying the downregulation of neuronal lineage-specific genes upon NBAT-1 downregulation. A neuron restrictive silencing factor NRSF/ REST, which represses the expression of neuronal genes in nonneuronal tissues and embryonic stem cells, was upregulated upon NBAT-1 downregulation (Figures 8A and S7A) . Also, an increased expression of NRSF/REST was found in MNA tumors relative to non-MNA tumors in the R2 data set (Figure S7B) . Interestingly, a significant proportion of NBAT-1 affected neuronal genes (cluster IV) have NRSF/REST binding sites, characterized in a publically available ChIP-seq data set ( Figure 8B ; Table S9 ) (Wang et al., 2012b) , indicating that NBAT-1 may control neural commitment via repressing the NRSF/REST pathway. Consistent with this notion, upregulation of several neuronal lineage-specific genes and restoration of the neuronal phenotype was observed when NRSF/REST was downregulated in the NBAT1-sh cells (Figures 8C, 8D, and  S7C ). It is also important to note that many REST targets such as KLF7, SYT2, and PIPOX are expressed at significantly lower levels in high-risk patients (Versteeg dataset from R2 database http://r2.amc.nl) ( Figure S7D ) and showed relaxation of their silencing upon NRSF/REST knockdown in the NBAT-1 downregulated SH-SY5Y cells ( Figure 8E ). Collectively, these observations indicate that the regulation of key genes required for proper neuronal differentiation occurs via a NBAT-1 regulated NRSF/REST pathway. Figure S5 and Table S6 .
DISCUSSION
In this study, we characterized differentially expressed lncRNAs between low-and high-risk neuroblastomas. We identified 24 lncRNAs, which can distinguish the high-risk tumors from lowrisk tumors. These noncoding signatures could serve as complementary information, alongside with established biomarkers such as amplification of the MYCN gene and heterozygous deletion of the 11q arm, for efficient stratification of the disease. In addition, this study also identified lncRNAs that map to commonly occurring nonrandom chromosome alterations, MNA, 1p deletion, and 11q deletion. LncRNAs that map to the amplicons on 2p associated with MNA and to the 11q deletion region could act as oncogene and tumor suppressor genes, respectively. Validation of their expression in an extended series of tumors suggests potential roles in the pathogenesis of MNA and 11q-tumors. Further characterization of the mode of action of these lncRNA would be needed to explain how their aberrant expression, due to genomic imbalances, might contribute to the pathogenesis of specific subtypes of the disease.
The current investigation implicates NBAT-1 expression as an independent prognostic marker in patients with neuroblastoma. This RNA is expressed at lower levels in high-risk (both 11q-and MNA) tumors, and its lower expression could serve as a risk factor to predict adverse outcome among neuroblastoma patients. Our study suggests that multiple factors contribute to differential expression of NBAT-1 among the neuroblastoma subtypes. Hypermethylation at the NBAT-1 promoter in high-risk patients indicates that DNA methylation is one of the primary mechanisms that contribute to NBAT-1 repression in these patients. In addition, we show that there is a functional correlation between NBAT-1 expression and the previously identified high-risk associated SNP (rs6939340) on 6p22 in intron 2 of the NBAT-1 gene (Maris et al., 2008) . Thus, our study demonstrates that both genetic and epigenetic changes underlie the differential expression of NBAT-1 in neuroblastoma subtypes.
Our cell culture and mouse xenograft models clearly demonstrate that NBAT-1 has tumor suppressor properties, such as anticell proliferation and anticell invasion. In this context, detailed investigation of the NBAT-1 target genes revealed an interconnected network of affected genes ( Figure 5J) . Some of the genes present in this network (SOX9, VCAN, and OSMR) have been shown to contribute to tumor progression in several cancer types. Loss of proliferative and invasive properties of NBAT1-sh cells upon downregulation of SOX9, OSMR, and VCAN indicates that NBAT-1 controls tumor progression by suppressing these genes. The higher expression of SOX9 and VCAN genes in high-risk tumors compared to low-risk neuroblastoma tumors in our and R2 data sets further supports their functional role in tumor progression in high-risk neuroblastomas. Importantly, SOX9 maps to 17q24, and the gain of 17q is the most frequent abnormality in neuroblastoma tumors with poor prognosis (Caré n et al., 2010; Lastowska et al., 2001) . Collectively, these observations further emphasize the functional role of SOX9 in neuroblastoma tumor progression. Our data demonstrates that NBAT-1 epigenetically controls the expression of target genes involved in cell proliferation and cell invasion by interacting with EZH2. Upregulation of NBAT-1 target genes implicated in cell proliferation and invasion in both EZH2 and NBAT-1 knockdown cells and loss of H3K27me3 from their promoter regions, suggest that a NBAT-1/EZH2 functional interaction may repress these genes in low-risk patients via chromatin level regulation. The decreased NBAT-1 expression in high-risk tumors could be the underlying cause for the increased cell proliferation and cell invasion in these tumors by activating SOX9 and VCAN dependent pathways. However, increased EZH2 expression has been observed in high-risk neuroblastoma tumors, and this has been functionally linked to increased cell proliferation (Wang et al., 2012a) . Considering that NBAT-1 is expressed at low level in high-risk tumors, we are tempted to speculate that NBAT-1 acts as a scaffold for the EZH2 recruitment, and that EZH2 is no longer recruited to repress NBAT-1/EZH2 target genes in the absence of NBAT-1 expression, thus increasing the expression of genes involved in tumor progression ( Figure 8F ). Consistent with this idea, overexpression of EZH2 in NBAT1-sh cells had no significant effect on the expression of SOX9, OSMR, and VCAN genes (data not shown).
Another interesting aspect of the current study is NBAT-1's functional role in RA induced neuronal differentiation. Impaired neuronal differentiation of neuronal precursor cells is one of the characteristic features of high-risk neuroblastomas (Nakagawara et al., 1993) . We demonstrate that the inability of NBAT1sh cells to achieve neuronal differentiation is due to upregulation of the NRSF/REST pathway and consequent downregulation of some of its key neuronal-specific genes ( Figure 8F ). Further-more, the restoration of neuronal phenotype and relaxation of silencing of some of the key neuronal-specific genes upon NRSF/REST downregulation in the NBAT1-sh cells, suggests that NBAT-1 controls the neuronal lineage commitment via regulating NRSF/REST activity. Increased expression of NRSF/REST in MNA tumors relative to non-MNA tumors in the Versteeg dataset from R2 database (http://r2.amc.nl), and the recent suggestion that HOXC9 induced regression of neuroblastoma tumors involves downregulation of NRSF/REST (Kocak et al., 2013) provides an explanation for the impairment of differentiation of neuronal precursor cells in high-risk patients. In addition, upregulation of NRSF/REST in medulloblastoma patients has also been shown to affect the differentiation of neural stem/progenitors into neurons (Su et al., 2006) . These observations clearly indicate that NBAT-1 mediated NRSF/REST suppression could be a critical pathway regulating the neuronal fate commitment. Disturbance in this pathway could be one of the underlying causes for neural related cancers that are a result of impairment of neuronal differentiation. The RNA-sequencing data of NBAT-1 and EZH2 downregulated cells indicate that the NBAT-1/EZH2 functional interaction does not have any functional role in the neural lineage commitment. Though EZH2 and NBAT-1 have critical roles in neurogenesis, they operate by different pathways, and this observation is consistent with the fact that downregulation of EZH2 promotes neurogenesis (Wang et al., 2012a) , while that of NBAT-1 impairs neuronal differentiation.
Taken together, these observations reveal that NBAT-1 is a biomarker for risk assessment for neuroblastoma tumors. Additionally, the role of NBAT-1 in cell proliferation, invasion, and neuronal differentiation elucidates mechanisms and gene networks involved in neuroblastoma tumor development and progression. Both NBAT-1 and its downstream effectors (SOX9 and NRSF/REST) could serve as potential targets for drug development and options for neuroblastoma clinical treatment.
EXPERIMENTAL PROCEDURES
Patient and Tumor Material
Neuroblastoma primary tumors were obtained at surgery, snap frozen, and stored at À70 C until analysis. For RNA sequencing, a set of 15 tumors were selected: three clinical low-risk (Cohn et al., 2009 ) with a numerical only genotype (Caré n et al., 2010) , and 12 high-risk tumors with MYCN-amplification (n = 6) and 11q deletion (n = 6). In cohort I, a total of 106 Swedish and two German patients were included according to ethical permit number (Dnr 2011/354), it was approved by Regional Ethical Review Board, Uppsala University, Uppsala, and informed consent from the legal guardian was secured. In cohort II, RNA-seq data from 498 patients was used. These patients were Figure S6 and Table S8 . Figure S7 and Table S9 . Mouse Xenograft Tumor Model and Histology 3310 6 cells infected with either Cntrl-sh or NBAT1-sh (n = 9) were subcutaneously injected on the dorsal back region of 5-to 6-week-old Bagg Albino (inbred research mouse strain) nude male mice (Charles River Laboratories) as described earlier (Nallapalli et al., 2012) . Tumors were harvested and half of each tumor was frozen in liquid nitrogen and stored in À80 C, whereas the other half was fixed in 4% paraformaldehyde for immunostaining. All the mouse experiments were approved by Animal Ethical Review Board, University of Gothenburg, Gothenburg, Sweden (Ethical permit number-62/14). Paraffin-embedded tumor tissues were analyzed by hematoxylin and eosin staining (H&E). Immunostaining with Ki67 (Thermo Scientific) antibody was performed to detect the number of replicating cells as described earlier (Nallapalli et al., 2012) . Ki67 staining positivity was quantified in three different high power fields of each section, and the mean ±SD values were given.
RNA Isolation and Library Preparation
Tumors from neuroblastoma patients were cut on dry ice. Total RNA was isolated from the tumors using the Promega Total RNA Isolation Kit (Promega). Isolated RNA was ribo-depleted using the Ribominus Eukaryotic Kit (Invitrogen) according to the manufacturer's instructions. Ribo-depleted RNA was used to prepare a whole transcriptome library (Applied Biosystems) as per the manufacturer's protocol. Quality, size, and concentration of the RNA during library preparation were analyzed using Bioanalyser 2100 (RNA Pico Kit, Agilent). Final amplified cDNA library was analyzed using DNA Hypersensitive Kit (Agilent).
Pyrosequencing
Pyrosequencing was performed to analyze the methylation levels at five CpGs sites (labeled in Figure 4F ) at the NBAT-1 promoter. Genomic DNA from 13 tumors, each representing low-risk and high-risk tumors, were bisulphite converted and analyzed as described earlier (Martinelli et al., 2013) . The primers used for pyrosequencing analysis are mentioned in the Supplemental Experimental Procedures.
ACCESSION NUMBERS
The RNA sequencing files (FASTQ) have been deposited in European Nucleotide Archive (ENA) with study accession number: PRJEB6912 (http://www.ebi. ac.uk/ena/data/view/PRJEB6912). 
SUPPLEMENTAL INFORMATION
Supplemental Information includes
